Login / Signup

Improving the Affordability of Anticancer Medicines Demands Evidence-Based Policy Solutions.

Nora FranzenGiorgia RomagnoliAndreas ZieglerValesca P RetèlTheo J S OffermanWim H van Harten
Published in: Cancer discovery (2022)
The high cost of many new anticancer medicines significantly impedes breakthrough discoveries from reaching patients. A commonly heard refrain is that high prices are necessary to compensate for the high costs of research and development (R&D). Yet, there are promising policy proposals aimed at improving affordability without compromising innovation. In seeking new policy solutions, we argue for a shift away from entrenched opinion toward an evidence-based discourse that is grounded in experiments and real-world pilot studies. We offer a novel perspective and practical recommendations on how empirical evidence could and should be gathered to inform evidence-based policy interventions that lead to sustainable medicine prices in oncology. See related article by Franzen et al. (Cancer Res Commun 2022;2:39-47) .
Keyphrases
  • public health
  • healthcare
  • mental health
  • ejection fraction
  • end stage renal disease
  • newly diagnosed
  • physical activity
  • palliative care
  • randomized controlled trial
  • clinical trial
  • clinical practice
  • young adults